Exec. VP & Chairman

Shaker A. Mousa, PhD, MBA, FACC, FACB

Dr. Mousa was appointed as an endowed, tenured Professor and Executive Vice President and Chairman of the Pharmaceutical Research Institute (PRI) in 2002 and Vice Provost for Research at ACPHS in 2010. As the leader of PRI, Dr. Mousa works with scientists and students to identify novel strategies for unmet medical needs. Dr, Mousa and his staff have developed partnerships with other academic research centers in New York State’s Capital Region and academic and industrial centers nationally and worldwide.

He holds Adjunct Professor appointments at Rensselaer Polytechnic Institute, SUNY Albany, SUNY Buffalo, and Temple University. He is a Visiting Professor of Bioethics at Albany Medical College and a Visiting Scholar at Johns Hopkins University.

Previously, Dr. Mousa was a Senior Scientist and Fellow at DuPont Pharmaceutical Company for about 2 decades where he served as a Working Group Chair of several drug discovery programs from 1993-2001.

Dr. Mousa holds more than 350 US and International Patents discovering novel anti-angiogenesis strategies, antithrombotics, anti-integrins, anti-cancer, and non-invasive diagnostic imaging approaches. His has published more than 500 journal articles, book chapters, and books as author and editor. His research has focused on diagnostics and therapeutics of angiogenesis-related disorders, thrombosis, and vascular diseases.

Dr. Mousa received his BSC from Alexandria University, College of Pharmacy & Pharmaceutical Sciences with distinction, ranking first in a class of over 500 Pharmacy students. He was then appointed a member of the faculty, and he received his MSC in Biochemical Pharmacology. He received his PhD from Ohio State University, College of Medicine, in Columbus, OH, and did a Postdoctoral Fellowship at the University of Kentucky, Lexington. He has also received his MBA (Management) from Widener University, Chester, PA.


Dr Mousa has over 65 US and International Patents.

NIH Study Sections & other committees that Dr. Mousa serves on:

Member of NIH Study Section Fellowships (F30-F33)

Member of NIH Study Section for R21, R15, R03 Vascular Biology

Member of NIH Scientific Advisory Committee

Member of NIH Study Sections SBIR/STTR (Pulmonary and Oncology)

Member of Department of Defense Study Section

Member: Several ad hoc NIH study sections

Member of various pharmaceutical and biotech companies grant review committees

Reviewer for the Swiss National Science Foundation, the Australian National Science Foundation, and several other foundations

Small Business: Respiratory Sciences (SBIR/STTR)

Fellowships: Physiology and Pathobiology of Cardiovascular and Respiratory Systems (F30-F33)


  • Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

    T Sudha, DJ Bharali, M Yalcin, NHE Darwish, M Debreli Coskun, KA Keating, H-Y Lin, PJ Davis, SA Mousa (2017)
    Nanomedicine 12(3):195-205.

    Read more
  • Self-assembly of green tea catechin derivatives in nanoparticles for oral lycopene delivery

    W Li, M Yalcin, Q Lin, MM Ardawi, SA Mousa (2017)
    Journal of Controlled Release 248:117-124

    Read more